Trial Profile

Amlodipine + perindopril versus atenolol + bendroflumethiazide in hypertensive patients with hyperlipidaemia with or without atorvastatin.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amlodipine (Primary) ; Atenolol (Primary) ; Atorvastatin (Primary) ; Bendroflumethiazide; Perindopril
Indications Cardiovascular disorders; Coronary artery disease; Essential hypertension; Myocardial infarction
Focus Therapeutic Use
Acronyms ASCOT; ASCOT-10; ASCOT-BPLA; ASCOT-LLA; CAFE; CAFE-DIABETES; CARAT; EVIREST

26 Aug 2018 16-Year follow-up results published in The Lancet.
30 Aug 2017 Results of post hoc analysis of ASCOT lipid lowering arm evaluating safety and efficacy among patients treated with amlodipine, perindopril atorvastatin or placebo presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
02 Sep 2015 Substudy results presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com